NCT02314325 - Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

May 31, 2016

Study Completion Date

October 31, 2016

Conditions

Severe Haemophilia A

Interventions

DRUG

ADVATE [Antihemophilic Factor (Recombinant)]

In Arm 1 prior patients will be dosed as per body weight 20-40 IU/kg 5-7 infusions per fortnight

DRUG

ADVATE [Antihemophilic Factor (Recombinant)]

In Arm 2 patients who have completed arm 1 will cross over onto an individualised PK tailored alternate day dosing regimen

Trial Locations (1)

RECRUITING

St. James's Hospital, Dublin